U.S. Markets closed
  • S&P 500

    4,305.20
    +8.06 (+0.19%)
     
  • Dow 30

    34,152.01
    +239.61 (+0.71%)
     
  • Nasdaq

    13,102.55
    -25.55 (-0.19%)
     
  • Russell 2000

    2,020.53
    -0.82 (-0.04%)
     
  • Crude Oil

    86.96
    +0.43 (+0.50%)
     
  • Gold

    1,774.90
    +1.70 (+0.10%)
     
  • Silver

    20.09
    +0.01 (+0.05%)
     
  • EUR/USD

    1.0173
    +0.0002 (+0.0203%)
     
  • 10-Yr Bond

    2.8240
    +0.0330 (+1.18%)
     
  • Vix

    19.69
    -0.26 (-1.30%)
     
  • GBP/USD

    1.2096
    +0.0002 (+0.0133%)
     
  • USD/JPY

    134.2860
    +0.0710 (+0.0529%)
     
  • BTC-USD

    23,884.50
    -257.30 (-1.07%)
     
  • CMC Crypto 200

    569.15
    -2.76 (-0.48%)
     
  • FTSE 100

    7,536.06
    +26.91 (+0.36%)
     
  • Nikkei 225

    28,868.91
    -2.89 (-0.01%)
     

ProPhase Labs to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GARDEN CITY, NY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

The presentation will be available on-demand beginning at 7:00 a.m. ET on Monday, January 10, 2022, to H.C. Wainwright registered attendees of the conference.

Register for the conference here: https://hcwevents.com/bioconnect/

About ProPhase Labs

ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a diversified biotech and genomics company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing. ProPhase Precision Medicine, Inc. focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

ProPhase Diagnostics offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories. ProPhase Diagnostics serves patients who may have SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods. Critical to COVID testing, results are provided in under 24 hours. ProPhase Diagnostics also offers PCR (polymerase chain reaction) testing for Influenzas A and B as well as antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

ProPhase Global Healthcare, Inc. was formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.

ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements® brand. ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products. For more information, visit www.ProPhaseLabs.com.

Media Relations Contact:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com